Publications by authors named "Matteo Zanuzzi"
Article Synopsis
- The study explores the gap between expected and actual spending on orphan drugs in Italy, focusing on financial aspects during the pricing and reimbursement negotiations.
- The analysis involved 52 orphan drugs authorized by the European Medicines Agency and revealed that actual spending was generally 7.6% lower than anticipated after negotiations, particularly for innovative drugs.
- Payment-by-result agreements were found to be a significant factor affecting the differences in expected spending before and after negotiations.
Objective: The main objective of this study was to explore the extent to which the incremental cost-effectiveness ratio (ICER), alongside other factors, predicts the final outcome of medicine price negotiation in Italy. The second objective was to depict the mean ICER of medicines obtained after negotiation.
Methods: Data were extracted from company dossiers submitted to the Italian Medicines Agency (AIFA) from October 2016 to January 2021 and AIFA's internal database.
Objective: The main objective of this study was to evaluate the potential role of efficacy data and other information available at the time of price and reimbursement (P&R) decision-making process within the definition of oncology treatment costs in Italy.
Methods: The study included all P&R dossiers submitted to the Italian Medicines Agency between July 2015 and December 2017. It prospectively collected the data of the P&R process starting from dossier submission up to the Italian Health Service reimbursement decision.
Quality of health economic evaluations submitted to the Italian Medicines Agency: current state and future actions.
Int J Technol Assess Health Care
December 2020
Objectives: The purpose of this study was to evaluate the current state of health economic evaluations (HEEs) submitted by pharmaceutical companies to the Italian Medicines Agency (AIFA) as part of their pricing and reimbursement (P&R) dossiers, and to explore potential future actions in order to enhance their quality.
Methods: All company dossiers submitted from October 2016 to December 2018 were reviewed to select those containing pharmacoeconomic studies. The general characteristics of HEEs were described and their quality assessed based on a checklist adapted from Philips et al.